Indivior declares $8.13 per share special dividend tied to Supernus merger closing
The dividend will only be paid if Indivior's pending merger with Supernus Pharmaceuticals closes, expected on or about November 2, 2026.
SEC filing
Latest
7 stories
Thursday, September 17
Tuesday, September 15
Indivior and Reckitt Benckiser move up end date of Suboxone/Subutex supply deal
The companies agreed to end their manufacturing arrangement early, on January 15, 2027, as Indivior transitions to a new supplier.
SEC filing
Monday, August 3
Indivior and Supernus agree to merger of equals
The two CNS-focused drugmakers plan to combine into a single company with about $2.2 billion in pro forma net revenue, targeting a close in the fourth quarter of 2026.
SEC filing
Indivior raises 2026 guidance on record SUBLOCADE revenue
The company reported second-quarter 2026 results on August 3 and lifted its full-year revenue and profitability targets while its planned merger with Supernus is expected to close in the fourth quarter.
SEC filing
Supernus and Indivior agree to all-stock merger of equals
The companies will combine into Supernus, Inc., a CNS-focused biopharmaceutical company, with closing expected in the fourth quarter of 2026.
SEC filing
Supernus and Indivior agree to merge as Supernus reports second-quarter growth
Supernus announced a definitive all-stock merger of equals with Indivior on the same day it posted 32% revenue growth and raised full-year guidance.
SEC filing
Indivior and Supernus agree to merge, forming Supernus, Inc.
Indivior will absorb Supernus in a stock-for-stock deal that renames the combined company and pays holders a $1 billion special dividend.
SEC filing